# Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

> **NCT03565536** · PHASE2 · COMPLETED · sponsor: **Fujian Medical University** · enrollment: 18 (actual)

## Conditions studied

- Thyroid Cancer, Anaplastic

## Interventions

- **DRUG:** Nexavar
- **PROCEDURE:** operation
- **RADIATION:** External radiation therapy

## Key facts

- **NCT ID:** NCT03565536
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565536, "Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03565536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*